Back to Search
Start Over
Respiratory syncytial virus-approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors.
- Source :
-
The Journal of biological chemistry [J Biol Chem] 2023 Nov; Vol. 299 (11), pp. 105270. Date of Electronic Publication: 2023 Sep 19. - Publication Year :
- 2023
-
Abstract
- Synthetic cytokine receptors can modulate cellular functions based on an artificial ligand to avoid off-target and/or unspecific effects. However, ligands that can modulate receptor activity so far have not been used clinically because of unknown toxicity and immunity against the ligands. Here, we developed a fully synthetic cytokine/cytokine receptor pair based on the antigen-binding domain of the respiratory syncytial virus-approved mAb Palivizumab as a synthetic cytokine and a set of anti-idiotype nanobodies (AIP <superscript>VHH</superscript> ) as synthetic receptors. Importantly, Palivizumab is neither cross-reactive with human proteins nor immunogenic. For the synthetic receptors, AIP <superscript>VHH</superscript> were fused to the activating interleukin-6 cytokine receptor gp130 and the apoptosis-inducing receptor Fas. We found that the synthetic cytokine receptor AIP <superscript>VHH</superscript> gp130 was efficiently activated by dimeric Palivizumab single-chain variable fragments. In summary, we created an in vitro nonimmunogenic full-synthetic cytokine/cytokine receptor pair as a proof of concept for future in vivo therapeutic strategies utilizing nonphysiological targets during immunotherapy.<br />Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Palivizumab pharmacology
Palivizumab therapeutic use
Receptors, Cytokine
Cytokines
Ligands
Antiviral Agents pharmacology
Antiviral Agents therapeutic use
Receptors, Artificial metabolism
Receptors, Artificial therapeutic use
Respiratory Syncytial Virus Infections drug therapy
Respiratory Syncytial Virus, Human
Subjects
Details
- Language :
- English
- ISSN :
- 1083-351X
- Volume :
- 299
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- The Journal of biological chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 37734558
- Full Text :
- https://doi.org/10.1016/j.jbc.2023.105270